Drugs / alloreactive CTL
alloreactive CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01144247 | Jul 2010 → Jul 2015 | anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, meningioma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alloreactive CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01144247 ↗ |
| Known as | alloCTL | “cellular immunotherapy with alloCTL” NCT01144247 ↗ |
| Known as | alloreactive cytotoxic T lymphocytes | “intracavitary alloreactive cytotoxic T lymphocytes (CTL)” PMID 9390198 ↗ Oct 1997 |
| Action | Deplete | “offer selective, targeted killing of glioma cells” PMID 9390198 ↗ Oct 1997 |
| Modality | Cell therapy | “cellular immunotherapy with alloCTL” NCT01144247 ↗ |
| Route | Other | “CTL were implanted into the tumor bed at surgery” PMID 9390198 ↗ Oct 1997 |